Friday, November 6, 2026

CBOE Bullish Momentum With A 17% Jump In The Last 21 Sessions

ViaNews Editorial Team

October 10, 2024

CBOE Bullish Momentum With A 17% Jump In The Last 21 Sessions

(VIANEWS) - CBOE (VIX) has been up by 17.81% for the last 21 sessions. At 16:08 EST on Thursday, 10 October, CBOE (VIX) is $20.84.

About CBOE's yearly highs and lows, it's 34.19% up from its 52-week low and 40.54% down from its 52-week high.

Volatility

CBOE's last week, last month's, and last quarter's current intraday variation average was 0.71%, 0.52%, and 7.89%, respectively.

CBOE's highest amplitude of average volatility was 8.23% (last week), 5.35% (last month), and 7.89% (last quarter), respectively.

News about

  • According to FXStreet on Tuesday, 8 October, "Today's session is likely to open on a positive note, with the S&P 500 rebounding after yesterday's nearly 1% decline. ", "The S&P 500 continues to trade within a consolidation, as we can see on the daily chart."
  • According to Zacks on Tuesday, 8 October, "Tuesday, October 8th, 2024Pre-market futures look to build back from the sell-off in Monday's session, which saw the Dow slide -0.94%, the S&P 500 -0.96% and the Nasdaq -1.18%. ", "Of course, we've already begun to have S&P 500 companies report for Q3, including Pepsi (PEP Quick QuotePEP - Free Report) this morning (it beat by a penny) and Delta Air Lines (DAL Quick QuoteDAL - Free Report) on Thursday. "
  • According to FXStreet on Tuesday, 8 October, "For example, the S&P 500 is down a mere 1.5% Quarter to date, the Eurostoxx 50 index is down just over 1% on a USD basis. ", "Since the start of Q4, the S&P 500 has outperformed medium-sized companies on the Russell 2000 and it has also outperformed the Dow Jones. "

More news about CBOE (VIX).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com
CBOE Bullish Momentum With A 17% Jump In The Last 21 Sessions | Via News